STOCK TITAN

ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

ASLAN Pharmaceuticals (Nasdaq:ASLN), an immunology-focused biopharmaceutical company, announced that CEO Dr. Carl Firth will present at the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The virtual presentation will be accessible on demand starting January 10, 2022, at 07:00 AM ET through ASLAN's Investor Relations website. ASLAN is developing innovative treatments, including ASLAN004 for atopic dermatitis and ASLAN003 for autoimmune diseases, highlighting its commitment to transforming patient lives.

Positive
  • None.
Negative
  • None.

MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright Bioconnect Conference on January 10, 2022. The conference will be held virtually from January 10 to January 13, 2022.

An on demand recording of the presentation will be available from January 10, 2022, at 07:00am ET in the News & Events section of ASLAN’s Investor Relations website at https://ir.aslanpharma.com/ and at the following link: https://journey.ct.events/view/849b8055-6a56-4b5b-a566-276449282256

Media and IR contacts

Emma Thompson
Spurwing Communications
Tel: +65 6206 7350
Email: ASLAN@spurwingcomms.com

Ashley R. Robinson
LifeSci Advisors, LLC
Tel: +1 (617) 430-7577
Email: arr@lifesciadvisors.com

About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.


FAQ

What is the date of ASLAN Pharmaceuticals' presentation at the H.C. Wainwright Bioconnect Conference?

The presentation is scheduled for January 10, 2022.

How can I access the ASLAN Pharmaceuticals presentation recording?

The on-demand recording will be available on ASLAN's Investor Relations website starting January 10, 2022, at 07:00 AM ET.

What treatments is ASLAN Pharmaceuticals currently developing?

ASLAN is developing ASLAN004 for atopic dermatitis and ASLAN003 for autoimmune diseases.

Where is ASLAN Pharmaceuticals located?

ASLAN Pharmaceuticals has teams in Menlo Park, California, and Singapore.

Who is the CEO of ASLAN Pharmaceuticals?

The CEO of ASLAN Pharmaceuticals is Dr. Carl Firth.

ASLAN Pharmaceuticals Limited American Depositary Shares

NASDAQ:ASLN

ASLN Rankings

ASLN Latest News

ASLN Stock Data

1.70M
2.82M
0.14%
13.21%
1.35%
Biotechnology
Healthcare
Link
United States of America
Singapore